2000 Participants Needed

Pharmacogenomics Testing for Overmedication

RU
Overseen ByRyley Uber, Pharm.D.
Age: 65+
Sex: Any
Trial Phase: Academic
Sponsor: Geisinger Clinic
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The primary goal of this study is to conduct pharmacogenomics testing (a type of DNA test) within an aging population and measure the impact of this test on medication selection, dosing, healthcare utilization, and costs of care.

Do I need to stop my current medications for the trial?

The trial protocol does not specify whether you need to stop your current medications. However, since the study involves testing the impact of DNA testing on medication selection and dosing, it's possible that changes to your medication regimen could occur.

Is pharmacogenomics testing generally safe for humans?

Pharmacogenomics testing is generally considered safe and can help predict adverse drug reactions (unwanted side effects) by using a person's genetic information. Studies have shown that using pharmacogenomics can reduce the risk of harmful drug reactions, as seen in a European study where it lowered the risk of toxicities by 30%.12345

How does the multigene pharmacogenomics test differ from other treatments for overmedication?

The multigene pharmacogenomics test is unique because it uses genetic testing to understand how a person's body processes different drugs, helping to prevent overmedication by tailoring drug prescriptions to individual genetic profiles. This approach is different from standard treatments, which often do not consider genetic differences in drug metabolism.56789

What data supports the effectiveness of the treatment Multigene pharmacogenomics test for overmedication?

Research shows that pharmacogenetic testing can improve health outcomes by reducing side effects and the number of drugs used, especially in patients taking multiple medications. This suggests that using pharmacogenomics tests can help manage overmedication by tailoring drug treatments to individual genetic profiles.56101112

Who Is on the Research Team?

RU

Ryley Uber, Pharm.D.

Principal Investigator

Geisinger Clinic

Are You a Good Fit for This Trial?

This trial is for older adults who are patients at Geisinger 65 Forward clinics and take five or more medications. It's not open to those who've had liver transplants, stem cell transplants, or were part of the eMERGE pharmacogenomics study.

Inclusion Criteria

I am currently taking 5 or more medications.
Follows at a Geisinger 65 Forward clinic location

Exclusion Criteria

I have had a stem cell transplant from a donor.
Previous enrollment in the Electronic Medical Records and Genomics (eMERGE) pharmacogenomics cohort
I have had a liver transplant.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Randomization

Participants are randomly assigned to either the pharmacogenomics testing group or the standard care group

1 week

Pharmacogenomics Testing

Participants in the experimental arm undergo a multigene pharmacogenomics test with results reported in the medical record

1 month
1 visit (in-person for blood draw)

Follow-up

Participants are monitored for changes in medication therapy, healthcare utilization, and costs of care

Up to 5 years

What Are the Treatments Tested in This Trial?

Interventions

  • Multigene pharmacogenomics test
Trial Overview The trial is testing a multigene pharmacogenomics test that examines DNA to guide medication choices and dosages for geriatric patients, aiming to improve healthcare outcomes and reduce costs.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Pharmacogenomics TestingExperimental Treatment1 Intervention
Group II: Standard of CareActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Geisinger Clinic

Lead Sponsor

Trials
159
Recruited
1,976,000+

Published Research Related to This Trial

A staggering 99% of veterans using VHA pharmacy services are projected to carry at least one actionable pharmacogenetic variant, indicating a high potential for personalized medicine to improve drug prescribing.
Over half of the veterans (54.8%) received at least one level A drug that could be influenced by these genetic variants, suggesting that pharmacogenetic testing could significantly impact treatment decisions for commonly prescribed medications.
Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users.Chanfreau-Coffinier, C., Hull, LE., Lynch, JA., et al.[2020]
Pharmacogenomics can help predict adverse drug reactions (ADRs) by identifying genetic variations that affect how individuals respond to medications, addressing a significant issue in drug safety.
The review highlights successful examples of pharmacogenomics influencing clinical practice and discusses future areas where it could improve drug safety, while also acknowledging the challenges in implementing these tests in healthcare.
The emerging era of pharmacogenomics: current successes, future potential, and challenges.Lee, JW., Aminkeng, F., Bhavsar, AP., et al.[2021]

Citations

Clinical use of pharmacogenomic tests in 2009. [2022]
The impact of pharmacogenetic testing in patients exposed to polypharmacy: a scoping review. [2023]
Implementation of pharmacogenetic testing in medication reviews in a hospital setting. [2023]
Implementation of Pharmacogenomics and Artificial Intelligence Tools for Chronic Disease Management in Primary Care Setting. [2021]
Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users. [2020]
The emerging era of pharmacogenomics: current successes, future potential, and challenges. [2021]
Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety. [2015]
Pharmacogenomic testing and antithrombotic therapy: ready for prime time? [2021]
Implementation of preemptive testing of a pharmacogenomic panel in clinical practice: Where do we stand? [2023]
10.United Statespubmed.ncbi.nlm.nih.gov
Pharmacogenomic Approaches for Automated Medication Risk Assessment in People with Polypharmacy. [2020]
Pharmacogenomic biomarkers: new tools in current and future drug therapy. [2011]
Frequencies of Combined Dysfunction of Cytochromes P450 2C9, 2C19, and 2D6 in an Italian Cohort: Suggestions for a More Appropriate Medication Prescribing Process. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security